<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17099" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Acne Fulminans</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Badri</surname>
            <given-names>Talel</given-names>
          </name>
          <aff>University of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Talel Badri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17099.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acne fulminans or acne maligna is a rare skin disorder presenting as an acute, painful, ulcerating, and hemorrhagic clinical form of acne. It may or may not be associated with systemic symptoms such as fever and polyarthritis. Acne fulminans also may cause bone lesions and laboratory abnormalities. The condition usually is resistant to the usual acne antibiotics. This activity reviews the etiology, epidemiology, evaluation, and management of acne fulminans and highlights the importance of a well-coordinated interprofessional team in caring for patients affected by this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the presentation of acne fulminans, including some of the systemic symptoms that may be present.</p></list-item><list-item><p>Identify the workup that should be done when evaluating for this condition.</p></list-item><list-item><p>Review the recommended treatment for patients with acne fulminans.</p></list-item><list-item><p>Outline strategies that interprofessional team members can utilize to improve evaluation, management, and counseling for patients with acne fulminans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17099&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17099">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17099.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acne fulminans or acne maligna is a rare skin disorder presenting as an acute, painful, ulcerating, and&#x000a0;hemorrhagic clinical form of acne. It may or may not be associated with systemic symptoms such as&#x000a0;fever&#x000a0;and polyarthritis. Acne fulminans also may cause bone lesions and laboratory abnormalities. Acne fulminans often is confused with acne conglobata. The condition usually&#x000a0;is resistant to the usual acne antibiotics.<xref ref-type="bibr" rid="article-17099.r1">[1]</xref><xref ref-type="bibr" rid="article-17099.r2">[2]</xref><xref ref-type="bibr" rid="article-17099.r3">[3]</xref></p>
      </sec>
      <sec id="article-17099.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Acne fulminans is a rare skin disorder, and hence its etiology is not well understood. Acne fulminans may be triggered by the use of high doses of isotretinoin when initiating treatment in patients with severe acne. Also, elevated levels of testosterone may&#x000a0;have a role in the pathogenesis. Anabolic steroids are known to increase levels of sebum and density of <italic toggle="yes">Propionibacterium acnes.</italic>&#x000a0;Bodybuilders who use anabolic steroids develop acne fulminans within a very short time. The belief is that&#x000a0;the density of <italic toggle="yes">P. acnes</italic> or related antigens triggers the immune system and leads to acne fulminans. Others believe&#x000a0;the condition&#x000a0;to&#x000a0;be autoimmune-mediated because circulating immune complexes have appeared in some patients with acne fulminans.<xref ref-type="bibr" rid="article-17099.r4">[4]</xref><xref ref-type="bibr" rid="article-17099.r5">[5]</xref></p>
        <p>Acne fulminans also has a genetic component, but the pattern of inheritance is not known.&#x000a0;The skin disorder may be part of the synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome (SAPHO), pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA), pyoderma gangrenosum, acne,&#x000a0;and hidradenitis&#x000a0;suppurativa syndrome (PASH), and pyogenic arthritis, pyoderma gangrenosum, acne,&#x000a0;and hidradenitis suppurativa syndrome (PAPASH).</p>
      </sec>
      <sec id="article-17099.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Less than 200 cases are known. The disorder usually affects young males, mainly of the White race, between 13 and 22 years of age. Most of these males have a prior history of acne. There also&#x000a0;are isolated reports of acne fulminans in females. There are globally-reported cases of this condition, but its incidence seems to be declining.</p>
      </sec>
      <sec id="article-17099.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Acne fulminans usually has a very&#x000a0;sudden onset, and the acne&#x000a0;often is ulcerating. Patients&#x000a0;may complain of fever and pain in multiple joints. They typically provide a history that the conventional antibiotics used for treating acne did not work. Most patients mention that&#x000a0;they did have acne in the past.</p>
        <p>Acne fulminans is similar to acne conglobata with numerous inflammatory nodules on the trunk. The nodules often are painful to touch, ulcerated, hemorrhagic, and covered with crusts. Unlike acne conglobata, there are cysts and acutely inflamed lesions, but there are no polyporous comedones. Painful splenomegaly and erythema nodosum&#x000a0;may be associated with systemic symptoms.</p>
        <p>Patients with acne fulminans&#x000a0;who have systemic symptoms may have a stooped posture due to bone and joint&#x000a0;pain. The inflammatory arthralgia usually affects more than one joint, typically the knees, hips, and pelvis.</p>
      </sec>
      <sec id="article-17099.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Because the disorder&#x000a0;may be associated with systemic symptoms, the workup should include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood cell count (CBC); may show elevated white blood cell (WBC) count with a large percentage of neutrophils, anemia of chronic disease, and/or leukemic-type reaction</p>
          </list-item>
          <list-item>
            <p>Erythrocyte sedimentation rate (ESR) and C-reactive protein&#x000a0;may&#x000a0;be elevated</p>
          </list-item>
          <list-item>
            <p>Liver function test</p>
          </list-item>
          <list-item>
            <p>Human chorionic gonadotrophin (blood or urine) in female patients</p>
          </list-item>
        </list>
        <p>
<bold>Imaging</bold>
</p>
        <p>Because of bone and joint pain, imaging frequently is&#x000a0;done. In the early stage, X-rays will only show reactive changes. About 50% of patients will demonstrate lytic lesions on a plain film X-ray, and the bone scan may show multiple areas of increased uptake. The lesions are destructive and often resemble acute osteomyelitis. Cultures of these bony lesions&#x000a0;are&#x000a0;often negative.</p>
      </sec>
      <sec id="article-17099.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The recommended treatment for acne fulminans is a combination of corticosteroids and isotretinoin. Oral corticosteroids should be started first at high doses (0.5 to 1 mg/kg/day)&#x000a0;for at least two weeks (at least four weeks if systemic symptoms) until lesions heal. Isotretinoin therapy can then start. The initial dose of isotretinoin should be 0.1 mg/kg/day in association with corticosteroids for four weeks. If there is no observable flare, maintain the same dose of isotretinoin for four more weeks, and corticosteroid doses&#x000a0;should undergo&#x000a0;gradual&#x000a0;tapering. Increasing isotretinoin doses should then progressively reduce to a minimum total dose of 120 mg/kg.<xref ref-type="bibr" rid="article-17099.r6">[6]</xref><xref ref-type="bibr" rid="article-17099.r7">[7]</xref><xref ref-type="bibr" rid="article-17099.r8">[8]</xref><xref ref-type="bibr" rid="article-17099.r9">[9]</xref></p>
        <p>In patients who remain adherent, relapses are rare. If a relapse does occur, a repeat cumulative dose of isotretinoin at 150 mg/kg is the recommendation. The treatment with isotretinoin lasts for many months as the initial dose is low.</p>
        <p>A recent review suggests that the use of additional&#x000a0;high-potency topical corticosteroids&#x000a0;may&#x000a0;result in a faster&#x000a0;response. Once healing occurs, the lesions become smaller, less tender, and have a minimal inflammatory reaction. Scarring is common.</p>
        <p>Acne fulminans does not respond to the traditional antibiotics used to treat the typical form of acne. Even when using these agents, the response is slow and incomplete.</p>
        <p>In the last few years, anecdotal reports have appeared after the use of biologics, such as etanercept and infliximab, in resistant patients. The response to these agents is effective and rapid. However, it is unknown if biologics will work in all patients. Several other targeted biologics also have been used to treat acne fulminans.</p>
        <p>
<bold>Other Treatments</bold>
</p>
        <p>Pulsed dye laser has shown moderate effectiveness, but adverse effects and pain remain an issue. Because the lesions are large, multiple treatments are required, and scarring and hypopigmentation are common complications.</p>
        <p>Reports suggest that diaminodiphenyl sulfone use may help ease the symptoms of acne fulminans in patients with ulcerative colitis.</p>
        <p>Combinations of prednisone with dapsone or cyclosporine also&#x000a0;have&#x000a0;been tried with success.</p>
        <p>Finally, the management of these patients is best with a dermatologist and an internist. Women of childbearing age should use great caution when using retinoids, as these agents are teratogenic. There is a registry of all patients who receive retinoids. All women who receive therapy with&#x000a0;isotretinoin should avoid getting pregnant for at least&#x000a0;one month after discontinuing the drug.</p>
      </sec>
      <sec id="article-17099.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acne and suppurative hidradenitis ( PASH) syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acne conglobata</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acne vulgaris</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bromoderma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Folliculitis decalvans</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Iododerma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rosacea fulminans</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe cystic acne</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17099.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Acne fulminans&#x000a0;is a devastating systemic disorder with severely disfiguring&#x000a0;skin lesions. The primary care provider and nurse practitioner should know that&#x000a0;this is a severe form of acne that should obtain a referral to a dermatologist.&#x000a0;&#x000a0;The majority of patients are affected negatively by the poor cosmesis. Their&#x000a0;quality of life is altered, and they are not able to participate in sports or social activities. Many become withdrawn and isolated. Thus, it is vital to offer psychosocial counseling to them. Many of these patients will benefit from mental health treatment and&#x000a0;the use of antidepressants. Suicidal ideation is very&#x000a0;common in these patients, and close follow up with a psychiatrist is highly recommended. The use of retinoids has not shown to worsen the risk of depression or suicidal ideation.<xref ref-type="bibr" rid="article-17099.r10">[10]</xref><xref ref-type="bibr" rid="article-17099.r11">[11]</xref></p>
        <p>The patient also has to be educated by clinicians, nurses, and pharmacists on the skin disorder and avoidance&#x000a0;of triggering agents. The skin should be kept clean and dry, the patient should discontinue smoking should, and one should refrain from applying unproven remedies like oils and ointments. An interprofessional team approach, including clinicians, specialists, nurses with specialty training in dermatology, and pharmacists, is most effective. [Level 5]</p>
      </sec>
      <sec id="article-17099.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17099&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17099">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/acne/acne-fulminans/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17099">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17099/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17099">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17099.s11">
        <title>References</title>
        <ref id="article-17099.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gualtieri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Panduri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiricozzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romanelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Isotretinoin-triggered acne fulminans: a rare, disabling occurrence.</article-title>
            <source>G Ital Dermatol Venereol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>361</fpage>
            <page-range>361-362</page-range>
            <pub-id pub-id-type="pmid">30229637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gualtieri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panduri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chiricozzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romanelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acne fulminans associated with lymecycline intake: a case report.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>403</fpage>
            <page-range>403-405</page-range>
            <pub-id pub-id-type="pmid">30122970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Antaya</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Isotretinoin-induced acne fulminans without systemic symptoms with concurrent exuberant granulation tissue.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-258</page-range>
            <pub-id pub-id-type="pmid">29314240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proen&#x000e7;a</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Acne fulminans.</article-title>
            <source>An Bras Dermatol</source>
            <year>2017</year>
            <volume>92</volume>
            <issue>5 Suppl 1</issue>
            <fpage>8</fpage>
            <page-range>8-10</page-range>
            <pub-id pub-id-type="pmid">29267432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massa</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Burmeister</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zouboulis</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Acne Fulminans: Treatment Experience from 26 Patients.</article-title>
            <source>Dermatology</source>
            <year>2017</year>
            <volume>233</volume>
            <issue>2-3</issue>
            <fpage>136</fpage>
            <page-range>136-140</page-range>
            <pub-id pub-id-type="pmid">28768255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Endicott</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-86</page-range>
            <pub-id pub-id-type="pmid">28656562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dessinioti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katsambas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Difficult and rare forms of acne.</article-title>
            <source>Clin Dermatol</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-146</page-range>
            <pub-id pub-id-type="pmid">28274350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siadat</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bostakian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abtahi-Naeini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shahbazi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Facial Acne Fulminans: Antimicrobial Agents and Oral Prednisolone as Promising Regimes.</article-title>
            <source>Case Rep Dermatol Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>7092910</fpage>
            <pub-id pub-id-type="pmid">28428896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navajas-Galimany</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Antunez-Lay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>When strength turns into disease: acne fulminans in a bodybuilder.</article-title>
            <source>An Bras Dermatol</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>706</fpage>
            <pub-id pub-id-type="pmid">27828663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Br&#x00103;ni&#x0015f;teanu</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Cotrutz</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Luca</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Molodoi</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Stoica</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Iano&#x0015f;i</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Cianga</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Br&#x00103;ni&#x0015f;teanu</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Morphopathological stigmata in acne fulminans.</article-title>
            <source>Rom J Morphol Embryol</source>
            <year>2015</year>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>1185</fpage>
            <page-range>1185-90</page-range>
            <pub-id pub-id-type="pmid">26662157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17099.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kraus</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Emmert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Haenssle</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder.</article-title>
            <source>Arch Dermatol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>10</issue>
            <fpage>1210</fpage>
            <page-range>1210-2</page-range>
            <pub-id pub-id-type="pmid">23069972</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
